[1]HUO N,CONG R,SUN ZJ,et al.STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis[J].Cell Death Dis,2021,12(9):799-801.
[2]COCA-PELAZ A,SHAH JP,HERNANDEZ-PRERA JC,et al.Papillary thyroid cancer-aggressive variants and impact on management:A narrative review[J].Adv Ther,2020,37(7):3112-3116.
[3]ARYANPOUR Z,ASBAN A,BOYD C,et al.A single institution experience with papillary thyroid cancer:Are outcomes better at comprehensive cancer centers[J].Am J Surg,2021,222(4):802-805.
[4]DONG S,XUE S,SUN Y,et al.MicroRNA-363-3p downregulation in papillary thyroid cancer inhibits tumor progression by targeting NOB1[J].J Investig Med,2021,69(1):66-74.
[5]ALI SYEDA Z,LANGDEN SSS,MUNKHZUL C,et al.Regulatory mechanism of microRNA expression in cancer[J].Int J Mol Sci,2020,21(5):45-48.
[6]HE B,ZHAO Z,CAI Q,et al.miRNA-based biomarkers,therapies,and resistance in cancer[J].Int J Biol Sci,2020,16(14):2628-2632.
[7]PAN G,LIU Y,SHANG L,et al.EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J].Cancer Commun(Lond),2021,41(3):199-217.
[8]SHI Y,LIU Z,LIN Q,et al.MiRNAs and cancer:Key link in diagnosis and therapy[J].Genes(Basel),2021,12(8):45-50.
[9]CHEN Y,MIN L,REN C,et al.miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer[J].PLoS One,2017,12(2):171-251.
[10]NAN Y,GUO L,LU Y,et al.miR-451 suppresses EMT and metastasis in glioma cells[J].Cell Cycle,2021,20(13):1270-1278.
[11]DOU R,LIU K,YANG C,et al.EMT-cancer cells-derived exosomal miR-27b-3p promotes circulating tumour cells-mediated metastasis by modulating vascular permeability in colorectal cancer[J].Clin Transl Med,2021,11(12):595-603.
[12]ZHANG H,YANG K,REN T,et al.miR-100-5p inhibits malignant behavior of chordoma cells by targeting IGF1R[J].Cancer Manag Res,2020,12(2):4129-4132.
[13]YE Y,LI SL,WANG JJ.miR-100-5p downregulates mTOR to suppress the proliferation,migration,and invasion of prostate cancer cells[J].Front Oncol,2020,10(1):578-584.
[14]LI X,REN Y,LIU D,et al.Role of miR-100-5p and CDC25A in breast carcinoma cells[J].PeerJ,2022,9(2):12-15.
[15]TAKEBAYASHI K,NASU K,OKAMOTO M,et al.hsa-miR-100-5p,an overexpressed miRNA in human ovarian endometriotic stromal cells,promotes invasion through attenuation of SMARCD1 expression[J].Reprod Biol Endocrinol,2020,18(1):31-35.
[16]ZHANG X,DENG Y,LIANG X,et al.miR-100-5p is a novel biomarker that suppresses the proliferation,migration,and invasion in skin cutaneous melanoma[J].Stem Cells Int,2022,22(2):585-590.
[17]MA P,HAN J.Overexpression of miR-100-5p inhibits papillary thyroid cancer progression via targeting FZD8[J].Open Med(Wars),2022,17(1):1172-1175.
[18]ZHANG S,DENG B,ZHANG Y,et al.Expression of miR-100 and RBSP3 in FTC-133 cells after exposure to 131I [J].Nucl Med Commun,2014,35(9):932-934.
[19]ABDULLAH MI,JUNIT SM,NG KL,et al.Papillary thyroid cancer:Genetic alterations and molecular biomarker investigations[J].Int J Med Sci,2019,16(3):450-456.
[20]YOU A,FU L,LI Y,et al.MicroRNA-203 restrains epithelial-mesenchymal transition,invasion and migration of papillary thyroid cancer by downregulating AKT3[J].Cell Cycle,2020,19(10):1105-1109.
[21]TANG Q,CHEN J,DI Z,et al.TM4SF1 promotes EMT and cancer stemness via the Wnt/beta-catenin/SOX2 pathway in colorectal cancer[J].J Exp Clin Cancer Res,2020,39(1):232-234.
[22]WANG G,YANG L,HU M,et al.Comprehensive analysis of the prognostic significance of hsa-miR-100-5p and its related gene signature in stomach adenocarcinoma[J].Front Cell Dev Biol,2021,9(2):736-740.
[23]PAN G,LIU Y,SHANG L,et al.EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J].Cancer Commun(Lond),2021,41(3):199-217.
[24]HUANG H.Matrix metalloproteinase-9(MMP-9)as a cancer biomarker and MMP-9 biosensors:Recent advances[J].Sensors(Basel),2018,18(10):10-23.
[25]马莉,伍洁,靳耀锋,等.三阴性乳腺癌中MMP-9的表达及意义[J].现代肿瘤医学,2017,25(22):3623-3626.
MA L,WU J,JIN YF,et al.The expression and significance of MMP-9 in triple negative breast cancer[J].Modern Oncology,2017,25(22):3623-3626.